Format

Send to

Choose Destination
Curr Opin Mol Ther. 2004 Dec;6(6):666-74.

Technology evaluation: cantuzumab mertansine, ImmunoGen.

Author information

1
Australian Nuclear Science and Technology Organisation, Materials Engineering and Science, Menai, NSW 2234. svs@ansto.gov.au

Abstract

ImmunoGen is developing cantuzumab mertansine, in which the CanAg antigen-targeted humanized antibody C242 is conjugated to the company's proprietary cytotoxic agent, DM1, using ImmunoGen's tumor-activated prodrug technology. Cantuzumab mertansine is undergoing phase II trials for the potential treatment of CanAg-expressing cancers, including pancreatic and colorectal cancers and non-small-cell lung cancer.

PMID:
15663331
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center